Trials / Sponsors / TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc.
Industry · 6 registered clinical trials — 2 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants Wit Advanced Or Metastatic Merkel Cell Carcinoma | Phase 2 / Phase 3 | 2025-12-11 |
| Recruiting | IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC) Advanced Or Metastatic Merkel Cell Carcinoma | Phase 1 | 2025-10-01 |
| Completed | IFx-Hu2.0 for the Treatment of Patients With Skin Cancer Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma | Phase 1 | 2021-06-10 |
| Completed | Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Non-Melanoma Skin Cancers | Phase 1 | 2020-03-03 |
| Completed | pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV | EARLY_Phase 1 | 2018-11-05 |
| Available | IFx-Hu2.0 Expanded Access Program Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV, Merkel Cell Carcinoma | — | — |